About Us

Treating, improving, and extending patients’ lives.

Our Vision

We are a clinical-stage biotech company dedicated to transforming outcomes in cardiothoracic surgical patients.

Renibus’ first-in-class lead program, RBT-1 (stannic protoporfin/iron sucrose), is a potent inducer of anti-inflammatory and antioxidant pathways. RBT-1 (stannic protoporfin/iron sucrose) has finished its Phase 2 development in cardiac surgery and will soon enter a Phase 3 registration study for its lead indication to reduce the risk of postoperative complications following cardiothoracic surgery.

RBT-3 (iron sucrose), a novel, low molecular weight iron nanoparticle, is one component of RBT-1 (stannic protoporfin/iron sucrose) and is targeted at rapidly resolving anemia and reducing the risk of cisplatin-induced nephrotoxicity and will be in Phase 2 clinical development in 2023.

RBT-9 (stannic protoporfin) is the other component of RBT-1, is a potent anti-inflammatory and anti-oxidant drug with select anti-viral properties. It has been in Phase 1 / 2 and is currently being evaluated for a future Phase 2 program.

RBT-2  is an antioxidant and anti-fibrotic drug that has been shown to reduce the risk of CKD progression in preclinical models. Currently in lead formulation stage.

Download Renibus Fact Sheet

Our Leadership Team


Read Frank's Bio

Frank Stonebanks

Read Jeff's Bio

D. Jeff Keyser, RPh, JD, PhD

Read Bhupinder's Bio

Bhupinder Singh, MD
Chief Medical Officer

Read Jamie's Bio

Jamie A. Donadio
Chief Financial Officer

Read Asha's Bio

Asha Ramdas
SVP, Program Management, Technical Operations and Manufacturing

Board of Directors

Henrik Rasmussen, MD, PhD
Frank Stonebanks
Co-CEO and Director
D. Jeff Keyser, RPh, JD, PhD
Co-CEO, Secretary and Director
Bhupinder Singh, MD
Carlos Guillem, MBA, PhD

Scientific Advisors

Alpesh Amin, MD, MBA, MACP, SFHM, FACC, FHFSA, FRCP (Lond)
Chair, Department of Medicine Professor of Medicine, Executive Director, Hospital Medicine. University of California, Irvine.
Rakesh Arora, BA, MD, PhD
Director – Perioperative and Cardiac Critical Care, Harrington Heart Vascular Institute, University Hospitals/Case Western Reserve University
Javed Butler, MD, MPH, MBA,
President of the Baylor Scott and White Research Institute. Senior Vice President for the Baylor Scott and White Health
Andre Lamy, MD, MSc
Cardiac Surgeon, Population Health Research Institute. McMaster University, Canada.
Kevin W. Lobdell, MD LTC, MC, USAR
Professor-System Director CV Surgical Quality, Education, & Research. Atrium Health – Sanger Heart & Vascular Institute.
Patrick T. Murray, MD, FASN, FRCPI, FJFICMI
Professor of Clinical Pharmacology at University College Dublin, Consultant Physician at the Mater Misericordiae. University Hospital, Dublin, Ireland.
Hamid Rabb, MD
Medical Director of the Johns Hopkins Kidney Transplant Program, Professor of Medicine. Johns Hopkins.
Andrew Shaw, MD, FRCA, FCCM, FFICM
Professor and Chair, Department of Intensive Care and Resuscitation, Cleveland Clinic.
Alexander Zarbock, MD, PhD
Professor of Anesthesiology and Intensive Care Medicine at the University of Münster and Chair of the Department of Anesthesiology, Intensive Care and Pain Medicine at the University Hospital Münster
Glenn M. Chertow, MD, MPH
Chief, Division of Nephrology, Stanford University School of Medicine
Norman S. Coplon Satellite Healthcare Professor in Medicine, Division of Nephrology, Stanford University School of Medicine

Laboratory of Basic
and Translational Research
Seattle, WA

Renibus’ translational lab, led by Dr. Richard Zager, keeps Renibus one step ahead of others in terms of innovating. This small, flexible and very efficient lab enables Renibus to get quick answers to important questions and explore new areas without the time and cost of outsourcing.

Richard A. Zager, MD
SVP Translational Research
Ali C.M. Johnson, MS
Staff Scientist